As of 2026-09-26, the Relative Valuation of Myriad Genetics Inc (MYGN) is (31.71) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.17 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -860.5%.
The range of the Relative Valuation is (27.42) - (30.88) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 23.0x - 30.4x | 28.0x |
| Forward P/E multiples | 21.2x - 25.9x | 25.2x |
| Fair Price | (27.42) - (30.88) | (31.71) |
| Upside | -757.5% - -840.5% | -860.5% |
| Date | P/E |
| 2026-09-25 | -3.50 |
| 2026-09-24 | -3.47 |
| 2026-09-23 | -3.36 |
| 2026-09-22 | -3.37 |
| 2026-09-21 | -3.36 |
| 2026-09-18 | -3.26 |
| 2026-09-17 | -3.47 |
| 2026-09-16 | -3.24 |
| 2026-09-15 | -3.25 |
| 2026-09-14 | -3.18 |
| 2026-09-11 | -2.87 |
| 2026-09-10 | -2.82 |
| 2026-09-09 | -2.68 |
| 2026-09-08 | -2.67 |
| 2026-09-04 | -2.68 |
| 2026-09-03 | -2.71 |
| 2026-09-02 | -2.71 |
| 2026-09-01 | -2.67 |
| 2026-08-31 | -2.70 |
| 2026-08-28 | -2.65 |
| 2026-08-27 | -2.67 |
| 2026-08-26 | -2.62 |
| 2026-08-25 | -2.68 |
| 2026-08-24 | -2.56 |
| 2026-08-21 | -2.68 |
| 2026-08-20 | -2.70 |
| 2026-08-19 | -2.68 |
| 2026-08-18 | -2.41 |
| 2026-08-17 | -2.56 |
| 2026-08-14 | -2.54 |
| 2026-08-13 | -2.66 |
| 2026-08-12 | -2.71 |
| 2026-08-11 | -2.70 |
| 2026-08-10 | -2.73 |
| 2026-08-07 | -2.73 |
| 2026-08-06 | -2.67 |
| 2026-08-05 | -2.64 |
| 2026-08-04 | -2.66 |
| 2026-08-03 | -2.53 |
| 2026-07-31 | -2.40 |
| 2026-07-30 | -4.50 |
| 2026-07-29 | -4.23 |
| 2026-07-28 | -4.46 |
| 2026-07-27 | -4.57 |
| 2026-07-24 | -4.71 |
| 2026-07-23 | -4.78 |
| 2026-07-22 | -4.75 |
| 2026-07-21 | -4.96 |
| 2026-07-20 | -4.97 |
| 2026-07-17 | -5.18 |